Medline (MDLN) Common Equity (2024 - 2026)

Medline (MDLN) has 3 years of Common Equity data on file, last reported at $11.3 billion in Q1 2026.

• On a quarterly basis, Common Equity changed N/A year-over-year to $11.3 billion in Q1 2026; TTM through Mar 2026 was $11.3 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $19.3 billion, up 19.36% from the prior year.
• Common Equity for Q1 2026 stood at $11.3 billion, down from $19.3 billion in the prior quarter.
• Over the last five years, Common Equity for MDLN reached as high as $19.3 billion in Q4 2025 and fell as low as $11.3 billion in Q1 2026.
• Historically, Common Equity has averaged $15.6 billion across 3 years, with a median of $16.2 billion in 2024.
• On a YoY basis, Common Equity climbed as much as 19.36% in 2025 and fell as far as 19.36% in 2025.
• Year by year, Common Equity stood at $16.2 billion in 2024, then rose by 19.36% to $19.3 billion in 2025, then sank by 41.55% to $11.3 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $11.3 billion in Q1 2026, $19.3 billion in Q4 2025, and $16.2 billion in Q4 2024.